Investigating how protein arginine methylation affects breast cancer progression
Protein arginine methylation in breast cancer
This study is looking at how a specific protein called CARM1 affects the growth and spread of triple-negative breast cancer, with the hope of finding new ways to treat this type of cancer that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11010374 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of protein arginine methylation in breast cancer, particularly in triple-negative breast cancer (TNBC). The study examines how the enzyme CARM1, which is overexpressed in TNBC, influences cancer cell growth and metastasis. By using inhibitors and genetic modifications, researchers aim to uncover the mechanisms by which CARM1 affects tumor behavior and the potential for new therapeutic strategies. Patients may benefit from insights that could lead to more effective treatments targeting this specific cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may benefit from novel treatment approaches.
Not a fit: Patients with other types of breast cancer or those who do not have a diagnosis of breast cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Xu, Wei — University of Wisconsin-Madison
- Study coordinator: Xu, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.